By Colin Kellaher

 

Roche Holdings AG's (ROG.EB) Genentech unit on Friday said a Phase 3 study of Tecentriq as an adjuvant monotherapy treatment missed its primary endpoint of disease-free survival in people with muscle-invasive urothelial cancer.

The company said safety for Tecentriq appeared consistent with the known safety profile of the immunotherapy drug, with no new safety signals identified.

"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival," Genentech said.

Genentech is conducting an extensive development program for Tecentriq, including ongoing and planned Phase 3 studies across bladder, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 24, 2020 07:37 ET (12:37 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Roche (QX) Charts.